• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Trump FDA pick to recuse himself from agency decisions involving 20 companies

March 29, 2017 By Sarah Faulkner

Trump FDA pick to recuse himself from agency decisions involving 20 companiesDonald Trump’s nominee to head the FDA, Dr. Scott Gottlieb, reportedly told ethics officials at the Office of Government Ethics he plans to recuse himself for 1 year from agency decisions on more than 20 companies, including GlaxoSmithKline (NYSE:GSK) and Bristol-Myers Squibb (NYSE:BMY).

Gottlieb has received millions of dollars for his roles as advisor, paid speaker and consultant to the companies, according to regulatory documents. He has also provided seed money for small, fledgling companies, advising them on regulatory matters.

Other capital came from New Enterprise Associates and from T.R. Winston & Co., where he has worked as a partner.

The FDA commissioner is not often required to intervene in company-specific decisions. Instead, they craft policy to cover entire industries. But Gottlieb’s involvement with a wide range of drug firms could be questioned by Senate Democrats in hearings next week, The Wall Street Journal reported.

In the last year, Gottlieb provided consulting work for GSK about the company’s research pipeline and the drug giant paid him $87,153 for his work.

At New Enterprise Associates, Gottlieb invested in 6 companies, including American Pathology Partners, Radiology Partners and U.S. Renal Care. He said he plans to divest interests in all of the companies.

Gottlieb’s critics said they are not as concerned about his finances as they are about his view of the FDA.

“You can’t recuse yourself from your ideology,” Harvard Medical School professor Jerome Avorn told the WSJ. “Scott has been very candid that he would like a lighter regulatory touch.”

The physician also served as deputy FDA commissioner under President George W. Bush.

“Every nominee who goes into government from private industry will have some recusals. But Scott brings a unique combination of experience. He understands how startups work, and it’s valuable for a regulator to understand this,” Gottlieb’s attorney, Leslie Kiernan, said.

Gottlieb has also received more than $200,000 in speaking fees in the last year, including $10,000 from Merck (NYSE:MRK) and $11,250 from Biogen (NSDQ:BIIB).

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Policy, Regulatory/Compliance, Wall Street Beat Tagged With: Biogen Idec, Bristol-Myers Squibb Co., GlaxoSmithKline plc, Merck

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS